BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121

Benzinga Newsdesk www.benzinga.com Negative 53.1%

Neg 53.1% Neu 0% Pos 0%

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.